Quantcast
Last updated on April 18, 2014 at 9:27 EDT

Latest Novocure Limited Stories

2014-04-03 12:29:26

HAIFA, Israel, April 3, 2014 /PRNewswire/ -- Novocure, a commercial stage oncology company, announced today that new, pre-clinical data demonstrating the anti-tumor effects of NovoTTF(TM) Therapy will be presented at the 2014 American Association for Cancer Research (AACR) in San Diego (April 5-9, 2014). The new study results show that ovarian cancer cells treated with Tumor Treating Fields (TTFields) exhibit abnormal chromosomal separation during cell division, reducing the viability of...

2014-02-18 08:32:26

The NovoTAL System Enables Certified Physicians to Plan and Individualize NovoTTF(TM) Therapy for Recurrent Glioblastoma Patients NEW YORK, Feb. 18, 2014 /PRNewswire/ -- Novocure announced today that Harvard Medical Faculty Physicians at Beth Israel Deaconess Medical Center has licensed the NovoTAL (Transducer Array Layout) System. The NovoTAL System allows certified physicians to use a recurrent GBM patient's MRI data to optimize the distribution and intensity of NovoTTF Therapy....

2014-01-24 08:24:33

HAIFA, Israel, Jan. 24, 2014 /PRNewswire/ -- Novocure announced today that the first patient has enrolled in the EF-20 Study, an open label, pilot clinical trial of NovoTTF Therapy plus gemcitabine as first-line therapy for patients with locally advanced and metastatic pancreatic adenocarcinoma. NovoTTF Therapy is an anti-mitotic treatment delivered continuously with a wearable, home-use medical device. "The EF-20 study builds on extensive preclinical research demonstrating the...

2014-01-06 08:27:57

HAIFA, Israel, Jan. 6, 2014 /PRNewswire/ -- Novocure(TM) announced today that the first evidence of activity of NovoTTF Therapy in pancreatic cancer tumor models was published online (December 16(th), 2013) in the prestigious peer reviewed journal Pancreatology. The published study showed that application of NovoTTF Therapy to pancreatic cancer cells in vitro leads to a significant decrease in cell count and reduced ability to form clones. Further analysis demonstrated a significant...

2013-12-10 12:33:10

CMS determined that a programmatic need existed for new dedicated billing codes as the NovoTTF-100A System delivers a distinct cancer treatment modality and has achieved widespread adoption following pre-market approval from the Food and Drug Administration for the treatment of confirmed recurrent glioblastoma NEW YORK, Dec. 10, 2013 /PRNewswire/ -- Novocure announced today that the Centers for Medicare and Medicaid Services (CMS) has established new therapy-specific Healthcare...

2013-11-21 08:28:39

The inovitro laboratory research system enables scientists to study the effects of Tumor Treating Fields in cancer cells. NEW YORK, Nov. 21, 2013 /PRNewswire/ -- Today, Novocure announced the launch of the inovitro, a propriety plug-and-play laboratory research system that allows scientists to apply Tumor Treating Fields (TTFields) to cancer cells in the lab. (Photo: http://photos.prnewswire.com/prnh/20131121/NY21742 ) "With the inovitro, researchers can, for the first time,...

2013-11-19 12:29:24

HAIFA, Israel, Nov. 19, 2013 /PRNewswire/ -- Novocure announced today that the first patients have enrolled in the EF-21 Study, a prospective randomized clinical study of NovoTTF(TM) Therapy for patients with brain metastases from non-small cell lung carcinoma (NSCLC) cancer. NovoTTF Therapy is an anti-mitotic treatment delivered continuously throughout the day by the NovoTTF-100A System. "The EF-21 Study builds on extensive preclinical research on the effect of NovoTTF Therapy in...

2013-11-05 08:36:35

The NovoTAL System Enables Certified Physicians to Plan and Individualize NovoTTF(TM) Therapy for Recurrent Glioblastoma Patients NEW YORK, Nov. 5, 2013 /PRNewswire/ -- Novocure announced today that the United States Food and Drug Administration (FDA) has approved the NovoTAL (Transducer Array Layout) System through a Premarket Approval (PMA) supplement. The NovoTAL System allows certified physicians to use the individual MRI data of recurrent glioblastoma multiforme (GBM) patients...

2013-07-31 12:27:37

Company Quickly Responds to Request for Compassionate Use of Alternating Electric Field Therapy ST. HELIER, Jersey, July 31, 2013 /PRNewswire/ -- Novocure today announced that Dr. Tatsunori Okamaura, MD, Ph.D., of the Kashiwaba Neurosurgical Hospital in Sapporo, Japan has treated the first patient in Japan with alternating electric field therapy. Dr. Okamaura is using NovoTTF Therapy to treat a recurrent glioblastoma tumor, the most common form of primary brain cancer worldwide....

2013-05-07 08:32:59

ST. HELIER, Jersey, May 7, 2013 /PRNewswire/ -- Novocure announced today that the EF-14 pivotal clinical trial for patients with newly diagnosed glioblastoma (GBM) brain tumors has enrolled its first patient in Korea. This randomized, controlled trial is designed to enroll approximately 700 patients and will test the efficacy and safety of NovoTTF(TM) Therapy when added to the current best standard of care for newly diagnosed GBM. NovoTTF Therapy is delivered by a portable, non-invasive...